It can be achieved through Wnt/β-Catenin and RXRA enhancing human cholangiocarcinoma growth through simultaneous activation of Wnt/β-Catenin and nuclear factor-kappa B pathways (NF-kappa B) to promote cancer proliferation [53]. The gene discussed is RXRA; the disease is cholangiocarcinoma.